Programming Cell Therapies to Overcome Solid Tumor Defense Systems


Manage episode 302423782 series 49047
By The Bio Report. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
While CAR-T cell therapies have emerged as promising anti-cancer agents, their success have been focused on hematologic cancers. ArsenalBio is working to develop more robust cell therapies capable to treating a broader range of cancers by using synthetic biology to make them programable. We spoke to Ken Drazen, CEO of ArsenalBio, about the company’s next-generation T cell therapies, how it is able to program functions into these cells to overcome solid tumor defenses, and the company’s collaboration with Bristol-Myers Squibb announced at the start of the year.

378 episodes